[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Laskar S, Bahl G, Muckaden MA, Nair R, Gupta S, Bakshi A, Gujral S, Shet T, Shrivastava SK, Dinshaw KA: Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer; 2007 Aug 15;110(4):816-23
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
  • BACKGROUND: The purpose was to evaluate the prognostic factors and treatment outcome of Indian patients with primary diffuse large B-cell lymphoma (DLBCL) of the tonsil treated at a single institution.
  • METHODS: In all, 121 patients with DLBCL of the tonsil, treated at the Tata Memorial Hospital, Mumbai, India, from January 1990 to December 2002, were included.
  • Treatment consisted of a combination of chemotherapy (CTh) and radiotherapy (RT) for the majority of patients (69.4%).
  • Among those receiving RT, 64% received an RT dose of > or =45 Gy.
  • The complete response (P = .053), DFS (P = .039), and OS (P = .014) rates were significantly better for patients receiving an RT dose > or =45 Gy.
  • A combined modality treatment, consisting of CTh and RT (with an RT dose of > or =45 Gy), results in a satisfactory outcome in patients with this uncommon neoplasm.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. India. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582622.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Mohammadianpanah M, Gramizadeh B, Omidvari Sh, Mosalaei A: Radiation-induced chondrosarcoma of the maxilla 7-year after combined chemoradiation for tonsillar lymphoma. J Postgrad Med; 2004 Jul-Sep;50(3):200-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced chondrosarcoma of the maxilla 7-year after combined chemoradiation for tonsillar lymphoma.
  • Radiation-induced sarcoma is a rare complication of radiation therapy.
  • An 80-year-old Persian woman developed radiation-induced chondrosarcoma of the left maxilla 7 years after combined chemotherapy and external beam radiation therapy for the Ann Arbor stage IE malignant lymphoma of the right tonsil.
  • [MeSH-major] Chondrosarcoma / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / radiotherapy. Maxillary Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Time Factors

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15377806.001).
  • [ISSN] 0022-3859
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. García Callejo FJ, Morant Ventura A, Tormos MM, Marco Algarra J: [Upper dysphagia due to a chemotherapy resistant Burkitt's lymphoma in a lingual tonsil]. Acta Otorrinolaringol Esp; 2003 Feb;54(2):109-12
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Upper dysphagia due to a chemotherapy resistant Burkitt's lymphoma in a lingual tonsil].
  • [Transliterated title] Disfagia alta por linfoma de Burkitt de amígdala lingual resistente a quimioterapia.
  • The exploration showed a tumour emerging in lingual tonsil and spreading out to hypopharynx and larynx.
  • Its resistance to chemotherapy made necessary its surgical removal.
  • [MeSH-major] Burkitt Lymphoma. Deglutition Disorders / etiology. Palatine Tonsil / pathology
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Female. HIV Seropositivity / complications. Humans

  • Genetic Alliance. consumer health - Dysphagia.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12802986.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, Bezombes C: Syk-dependent mTOR activation in follicular lymphoma cells. Blood; 2006 Dec 15;108(13):4156-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Syk-dependent mTOR activation in follicular lymphoma cells.
  • The mammalian target of rapamycin (mTOR) is emerging as a promising target for antitumor therapy.
  • This study shows that in follicular lymphoma (FL) cells, mTOR is active because the cells displayed rapamycin-sensitive phosphorylation of p70S6 kinase and 4E-BP1.
  • Moreover, immunohistochemistry applied on lymph node tissue sections obtained from patients with FL revealed that, in most cases, p70S6 kinase was highly phosphorylated compared to normal tonsillar tissue.
  • Finally, Syk inhibition by piceatannol or by siRNA plasmids resulted in a potent inhibition of mTOR activity in FL cells, as well as in mantle cell lymphoma, Burkitt lymphoma, and diffuse large B-cell lymphoma.
  • These findings suggest that the Syk-mTOR pathway has a critical function in FL survival, and therefore, that Syk could be a promising new target for B-lymphoma therapy.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / metabolism. Lymphoma, Follicular / enzymology. Neoplasm Proteins / metabolism. Protein Kinases / metabolism. Protein-Tyrosine Kinases / metabolism. Signal Transduction
  • [MeSH-minor] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / enzymology. Burkitt Lymphoma / pathology. Cell Line, Tumor. Enzyme Activation / drug effects. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / pathology. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / enzymology. Lymphoma, Mantle-Cell / pathology. Palatine Tonsil / enzymology. Palatine Tonsil / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Phospholipase D / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / pharmacology. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Stilbenes / pharmacology. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912221.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Stilbenes; 4339-71-3 / 3,3',4,5'-tetrahydroxystilbene; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 3.1.4.4 / Phospholipase D
  •  go-up   go-down


5. Cillessen SA, Reed JC, Welsh K, Pinilla C, Houghten R, Hooijberg E, Deurhof J, Castricum KC, Kortman P, Hess CJ, Ossenkoppele GJ, Meijer CJ, Oudejans JJ: Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood; 2008 Jan 1;111(1):369-75
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells.
  • Clinical outcome in patients with primary nodal diffuse large B-cell lymphomas (DLBCLs) is correlated with expression of inhibitors of the intrinsic apoptosis pathway, including X-linked inhibitor of apoptosis protein (XIAP).
  • In this study, we investigated to see if the small-molecule XIAP antagonist 1396-12 induces cell death in cultured lymphoma cells of patients with DLBCL.
  • Treatment with this XIAP antagonist resulted in relief of caspase-3 inhibition and in induction of apoptosis in 16 of 20 tested DLBCL samples.
  • Sensitivity to the XIAP antagonist was observed in both chemotherapy-refractory and -responsive DLBCL, but did not affect peripheral blood mononuclear cells and tonsil germinal-center B cells from healthy donors.
  • These data indicate that the small-molecule XIAP antagonist can induce apoptosis in cultured DLBCL cells and therefore should be considered for possible development as a therapy for these patients.
  • In vitro sensitivity to the XIAP antagonist can be predicted based on biological markers, suggesting the possibility of predefining patients most likely to benefit from XIAP antagonist therapy.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 May;6(5):1796-803 [10815900.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7012-21 [18056177.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1029-35 [10973324.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32438-43 [10961984.001]
  • [Cites] Blood Cells Mol Dis. 2001 Jan-Feb;27(1):206-16 [11358381.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2468-74 [11489828.001]
  • [Cites] Mol Pharmacol. 2001 Dec;60(6):1268-79 [11723234.001]
  • [Cites] J Pathol. 2002 Mar;196(3):307-15 [11857494.001]
  • [Cites] Cell Death Differ. 2003 Jul;10(7):853-5 [12815469.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):705-8 [14532997.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2081-9 [12970762.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):25-35 [14749124.001]
  • [Cites] Blood. 1993 Jan 1;81(1):151-7 [8417786.001]
  • [Cites] J Virol. 1993 Apr;67(4):2168-74 [8445726.001]
  • [Cites] Science. 1994 Nov 4;266(5186):807-10 [7973635.001]
  • [Cites] Nature. 1996 Jan 25;379(6563):349-53 [8552191.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2685-94 [8654366.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 1997 Jul 1;90(1):244-51 [9207459.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):300-4 [9230442.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):7787-90 [9525868.001]
  • [Cites] EMBO J. 1998 Apr 15;17(8):2215-23 [9545235.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3077-83 [10397248.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2478-82 [10452983.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5242-51 [10508158.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48168-76 [15337764.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1981-8 [15470488.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2916-23 [15576477.001]
  • [Cites] Blood. 2005 May 15;105(10):4043-50 [15687241.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1742-8 [15914559.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:215-9 [16304383.001]
  • [Cites] J Pathol. 2006 Apr;208(5):714-23 [16400625.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):283-93 [16848771.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):38-47 [17062006.001]
  • [Cites] Exp Cell Res. 2000 Jul 10;258(1):223-35 [10912804.001]
  • (PMID = 17916749.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / CA -113318; United States / NCI NIH HHS / CA / P01 CA-081534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antineoplastic Agents, Phytogenic; 0 / N-(6-((anilinocarbonyl)amino)-5-((anilinocarbonyl)((1-(4-cyclohexylbutyl)pyrrolidin-2-yl)methyl)amino)hexyl)-N-methyl-N'-phenylurea; 0 / Phenylurea Compounds; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 6PLQ3CP4P3 / Etoposide; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 9
  • [Other-IDs] NLM/ PMC2200818
  •  go-up   go-down


6. Jin YH, Park CK: Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications. J Korean Med Sci; 2002 Jun;17(3):322-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications.
  • To investigate the role of cyclin B1 and cdc2 in the pathogenesis and progression of malignant lymphoma, 68 cases of nodal non-Hodgkin's lymphoma were examined about the expression of cyclin B1 and cdc2 along with p53 and Ki-67 by immunohistochemical method.
  • The mean labeling indices of cyclin B1 and cdc2 in malignant lymphoma were 31.9% and 68.0%, respectively.
  • In normal lymphoid tissues, cyclin B1 and cdc2 were expressed predominantly in the germinal center with mean labeling indices of 13.9% and 28.3%, respectively.
  • The expression of cdc2 and p53 in complete remission group to chemotherapy was lower than that of progressive disease group (p=0.047, p=0.049).
  • In conclusion, cyclin B1 and cdc2 appeared to be involved in the genesis or progression of malignant lymphoma and cdc2 can be a useful marker for response to chemotherapy.
  • [MeSH-major] CDC2 Protein Kinase / biosynthesis. Cyclin B / biosynthesis. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cyclin B1. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Palatine Tonsil / metabolism. Palatine Tonsil / pathology. Predictive Value of Tests. Prognosis. Survival Analysis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068134.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.11.22 / CDC2 Protein Kinase
  • [Other-IDs] NLM/ PMC3054881
  •  go-up   go-down


7. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • METHODS: Clinical data of 89 naive patients with NHL of the tonsil, treated from May 1990 to Jan.
  • Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • Of the 89 patients, 58 (72%) received radiochemotherapy, 19 (21%) received radiotherapy alone, 3 received chemotherapy alone, and 1 received radiochemotherapy combined with rituximab.
  • Cox regression multivariate analysis showed that the survival rate was correlated to the value of international prognostic index (IPI), and whether the patient had primary refractory or relapsed disease, but was not correlated to sex, age, pathologic subtype, B symptoms, and bulky disease.
  • CONCLUSIONS: Most patients with NHL of the tonsil are at early stages, with good prognosis.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • Primary refractory, relapse, and IPI>1 are independent prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Souabni L, Elleuch M, Amira C, Sellami S: Malignant lymphoma of the tonsil in a patient with Behçet's disease. Joint Bone Spine; 2008 Oct;75(5):616-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the tonsil in a patient with Behçet's disease.
  • Several connective tissue diseases such as rheumatoid arthritis and polymyositis are associated with cancer.
  • We report a case of lymphoma during the course of Behçet disease.
  • A 46-year-old man with a 14-year history of Behçet disease was diagnosed with non-Hodgkin malignant lymphoma of the right tonsil.
  • He met international criteria for Behçet disease, which manifested as refractory oral ulcers requiring dapsone treatment.
  • He achieved a complete remission of the lymphoma after three chemotherapy courses and local radiation therapy (45 Gy).
  • [MeSH-major] Behcet Syndrome / pathology. Lymphoma, Non-Hodgkin / pathology. Tonsillar Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Remission Induction

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804394.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N: Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol; 2005 Apr;84(4):223-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of tonsillar lymphoma: a 10-year experience.
  • Primary extranodal non-Hodgkin's lymphomas of the head and neck account for 10-20% of all non-Hodgkin's lymphomas.
  • Primary tonsillar lymphoma accounts for less than 1% of head and neck malignancies, although the tonsil is the most common primary extranodal site of head and neck non-Hodgkin's lymphomas.
  • In this study we analyzed our cases of tonsillar lymphoma treated in our institution during the last 10 years to compare the finding of this study with those of previous studies.
  • We reviewed the cases of tonsillar lymphoma treated in the Radiation Oncology Department of Shiraz University from 1992 to 2002.
  • The patients were treated by combined chemotherapy [a median of six cycles of a CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisolone)] and radiation therapy (40-50 Gy to the primary site and neck).
  • Chemotherapy mainly preceded radiotherapy, although the sequence of radiotherapy and chemotherapy was determined by individual physicians and patients' choice.
  • Median and mean age was 48 and 44 years (range: 22-76 years), respectively, at the time of diagnosis, with a male to female ratio of 1.2:1.
  • The patients were treated by combined chemotherapy and radiation therapy.
  • All patients developed some degree of oropharyngeal mucositis.
  • A late fatal side effect was observed in one patient who developed radiation-induced sarcoma 7 years after initial diagnosis and died 8 months later without evidence of recurrent lymphoma.
  • At the time of last follow-up, all patients but one were alive.
  • Age, sex, stage, bulk of disease, performance status, number of chemotherapy cycles, number of involved sites, histologic subtypes, and radiation dose were analyzed as prognostically significant for disease-specific survival in our cases.
  • Combined chemotherapy and radiation therapy is safe, highly effective, and probably curative for most patients with primary tonsillar lymphoma.
  • [MeSH-major] Combined Modality Therapy / methods. Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant / adverse effects. Remission Induction / methods. Retrospective Studies. Risk Factors. Survival Rate. Tonsillectomy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15042316.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Yamazaki R, Takayama N, Hamano Y, Mori T, Okamoto S, Ikeda Y: [Localized recurrence of acute lymphoblastic leukemia-L3 in the tonsil after 3-years' remission]. Rinsho Ketsueki; 2002 Nov;43(11):1004-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localized recurrence of acute lymphoblastic leukemia-L3 in the tonsil after 3-years' remission].
  • Recurrence of Burkitt's lymphoma (BL)/acute lymphoblastic leukemia (ALL)-L3 after a long-term remission is very rare.
  • We herein report on a case of BL/ALL-L3 indicating solitary recurrence in the tonsil after a 3-year remission.
  • A 50-year-old man was diagnosed as having Burkitt's type ALL-L3 with involvement of the stomach and abdominal lymph nodes.
  • He was treated with intensive chemotherapy consisting of methotrexate and cyclophosphamide (ALL-BFM86 protocol), and a complete remission was achieved.
  • After sustaining the remission for three years, a swelling of the right tonsil was observed, which was histologically diagnosed as Burkitt's lymphoma.
  • The pattern of c-myc rearrangement of the tonsil demonstrated by southern blotting was identical to that of the bone marrow at initial presentation and the recurrence of primary ALL-L3/BL was thus confirmed.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Tonsillar Neoplasms / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Recurrence. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12508487.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Yoshitake K, Hagiwara Y, Tanae K, Takahashi N, Kohri M, Tamaru J, Bessho M, Niitsu N: [Marfan syndrome complicated with CD5+ CD10+ diffuse large B-cell lymphoma]. Rinsho Ketsueki; 2010 Mar;51(3):196-200
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Marfan syndrome complicated with CD5+ CD10+ diffuse large B-cell lymphoma].
  • His left tonsil gradually became swollen and he was referred to our department.
  • Histopathological examination of tonsil biopsy specimens showed diffuse proliferation of lymphoma cells with large nuclei.
  • Based on these findings, the patient was diagnosed with CD5+ CD10+ diffuse large B-cell lymphoma (DLBCL).
  • Chemotherapy combined with rituximab was administered and complete response was achieved.
  • There may be a relationship between MFS and B-cell lymphoma because mutations in the gene encoding the receptor of transforming growth factor-beta (TGF-beta) have been implicated in the pathogenesis of MFS and downregulation of TGF-beta receptor expression has been described in the pathology of B-cell lymphoma.
  • [MeSH-major] Antigens, CD5. Lymphoma, Large B-Cell, Diffuse / complications. Marfan Syndrome / complications. Neprilysin
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Down-Regulation. Gene Expression. Humans. Male. Microfilament Proteins / genetics. Mutation. Palatine Tonsil / pathology. Receptors, Transforming Growth Factor beta / genetics. Rituximab

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Marfan syndrome.
  • MedlinePlus Health Information. consumer health - Marfan Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379114.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD5; 0 / Microfilament Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / fibrillin; 4F4X42SYQ6 / Rituximab; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


12. Li Q, Li X, He Y: [Manifestations and management of malignant lymphoma in head and neck]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Jun;24(12):551-3
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Manifestations and management of malignant lymphoma in head and neck].
  • OBJECTIVE: To explore the clinical feature, treatment and prognosis of malignant lymphoma in head and neck.
  • METHOD: One hundred and sixteen cases with malignant lymphoma in head and neck were retrospectively analyzed.
  • The predilection site was most in head and neck (39.7%), followed by palate and tonsil (23.3%).
  • The treatment measures mainly included combined modality therapy and chemotherapy.
  • RESULT: Among 98 cases, of stage I and II, the survival time of 51 cases was more than one year, 24 cases were more than 3 years, 12 cases were more than 5 years.
  • CONCLUSION: clinical feature of malignant lymphoma in head and neck is nonspecific and complicated, misdiagnosis most easily occurs.
  • Biopsy is the most valuable in the diagnosis of malignant lymphoma.
  • Combined modality therapy is the mainstay of treatment in malignant lymphoma.
  • [MeSH-major] Head and Neck Neoplasms. Hodgkin Disease. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20806860.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Link MP, Devidas M, Murphy SB, Behm FG, Hutchison R: Favorable treatment outcome of children with early stage large B-cell and anaplastic large cell lymphomas. J Clin Oncol; 2004 Jul 15;22(14_suppl):8500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable treatment outcome of children with early stage large B-cell and anaplastic large cell lymphomas.
  • One hundred fifty-six (40%) had large cell lymphoma.
  • All patients received nine weeks of chemotherapy including vincristine 1.5mg/m2 weekly for seven doses; doxorubicin 40mg/m2 and cyclophosphamide 750mg/m2 on days 1, 22 and 43; and prednisone 40mg/m2 daily for 28 days during the first 4 weeks and on days 43-47.
  • Among children with DLBCL, primary sites included lymph nodes (13), GI tract (8), bone (8), tonsil (8), testis (3), and other (6).
  • Among children with ALCL, primary sites included lymph node (36), skin (11), bone (6), and other (5).
  • Only one patient with DLBCL developed recurrent disease and died.
  • At 5 years, the projected event-free survival (EFS) is 98 % (SE 3%), and the overall survival (OS), 98 % (SE 3%).
  • Nine patients with ALCL (T=5; null=4) failed treatment: three failed induction, and six relapsed from complete remission, but were effectively salvaged.
  • The projected 5 year EFS for early stage ALCL is 84 % (SE 7%) (DLBCL versus ALCL, p-value 0.02); the OS, 100%.
  • CONCLUSIONS: Nine weeks of modest intensity chemotherapy are sufficient for children with early stage DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ghobrial IM, McCormick DJ, Kaufmann SH, Ansell SM, Novak AJ, Stenson MJ, Krajnik KL, Witzig TE: Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):6530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy.
  • : 6530 Background: We employed antibody protein microarrays to measure changes in the patterns of protein expression between normal B-lymphocytes and those from patients with mantle cell lymphoma (MCL).
  • CD19+purified B-lymphocytes from a normal tonsil were used as control for all experiments.
  • Another patient with lymphoplasmacytic lymphoma (LPL) was performed for comparison to confirm that the pattern of expression is unique to MCL.
  • A control experiment of tonsil B-cell extracts was performed to ensure the absence of non-specific protein expression patterns.
  • RESULTS: Of the 6 MCL patients, 1 patient was heavily pretreated with chemotherapy and autologous stem cell transplantation and showed a distinct protein pattern from the other MCL patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016943.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gao Y, Li Y, Yuan Z, Zhao L, Liu X, Gu D, Qian T, Yu Z: [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):483-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil].
  • OBJECTIVE: To investigate the prognostic value of the size of primary tumor (T staging) and international prognostic index (IPI) for patients with non-Hodgkin's lymphoma (NHL) of the tonsil, and to recommend the treatment strategy for early stage patients.
  • METHODS: 306 patients with untreated NHL of the tonsil were reviewed.
  • Twelve stage I patients were given radiotherapy alone and 23 stage II patients were given combined modality therapy (CMT).
  • For patients with stage II lesion, 57 were given radiotherapy alone, 2 chemotherapy alone and 119 CMT.
  • Chemotherapy was the main treatment in patients with stage III or IV lesions.
  • RESULTS: The 5-year cancer specific survival (CSS) was 74% for patients with T(1), 59% for T(2), 56% for T(3) and 26% for T(4), respectively (P = 0.000).
  • CONCLUSION: The T staging of the primary tumor and IPI are the important prognostic factors of patients with NHL of the tonsil.
  • Combined modality therapy significantly improves the disease free survival of stage II patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Tonsillar Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485504.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Gao YH, Li YX, Zhao LJ, Yuan ZY, Liu XF, Yu ZH: [Treatment of early stage primary tonsil non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2003 Apr;24(4):190-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of early stage primary tonsil non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the treatment for patients with early stage primary tonsil non-Hodgkin's lymphoma (NHL).
  • METHODS: Two hundred and thirteen patients with previously untreated early stage primary tonsil NHL were reviewed.
  • The primary treatment for stage I was radiotherapy alone in 12 and combined modality therapy (CMT) in 23 patients.
  • The primary treatment for stage II was radiotherapy alone in 57,chemotherapy alone in 2, and CMT in 119 patients.
  • RESULTS: The 5-year overall survival, cancer specific survival (CSS) AND disease-free survival (DFS) for the early stage primary tonsil non-Hodgkin's lymphoma were 65%, 70% and 61%, respectively.
  • There was no significant difference of efficacy between the two treatment s for the patients with stage I disease.
  • CONCLUSION: Patients with stage I tonsil non-Hodgkin's lymphoma treated with radiotherapy alone or CMT can achieve an excellent outcome.
  • It was suggested that CMT should be used for the patients with early stage primary tonsil non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12864949.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Ree HJ, Kikuchi M, Lee SS, Ohshima K, Yang WI, Ko YH, Cho EY, Rhee JC: Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization. Hum Pathol; 2002 Jul;33(7):732-40
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization.
  • Focal follicular features in diffuse large B-cell lymphomas (DLBCLs) are bound to raise the question of follicular lymphoma (FL) with diffuse areas, because the diagnosis of FL is based on the presence of follicular areas, even though focal.
  • We report 7 cases of primary tonsillar DLBCLs with focal follicular features that presented with morphologic, immunohistochemical, and biological features distinct from those of FL.
  • Five of 7 patients were younger than 60, the median age of other patients with primary tonsillar DLBCL.
  • After chemotherapy or radiotherapy, complete remission was achieved with ease in all patients, but 2 patients who were treated with chemotherapy alone relapsed at 24 and 30 months.
  • In conclusion, tonsillar DLBCL includes a small (10%) but distinct subgroup that warrants distinction from FL with predominant diffuse areas or de novo DLBCL.
  • It appears that the focal follicular features in tonsillar DLBCL likely represent follicular colonization of marginal zone B-cell lymphoma, probably high-grade, if the possibility of FL is excluded.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Palatine Tonsil / pathology. Tonsillar Neoplasms / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12196925.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


18. Yamaguchi M, Maekawa M, Nakamura Y, Ueda M: Long-term remission of blastic natural killer-cell lymphoma after autologous peripheral blood stem-cell transplantation. Am J Hematol; 2005 Oct;80(2):124-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission of blastic natural killer-cell lymphoma after autologous peripheral blood stem-cell transplantation.
  • We report here a case of blastic natural killer (NK)-cell lymphoma treated successfully with autologous peripheral blood stem-cell transplantation (APBSCT).
  • A 57-year-old man had skin tumors and was diagnosed as having blastic NK-cell lymphoma by tumor biopsy.
  • Skin, lymph nodes, left tonsil, and bone marrow were involved at presentation.
  • Chemotherapy led to complete remission (CR).
  • To sustain CR, the patient underwent high-dose chemotherapy in combination with 12 Gy of total-body irradiation (TBI) followed by autologous peripheral blood stem-cell rescue.
  • From this case, we concluded that APBSCT with preconditioning by TBI-containing regimens might be a cure-attaining treatment for disseminated blastic NK-cell lymphoma and should be considered as a choice of treatment in cases where no suitable donors for allogeneic transplantation are available.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / therapy. Peripheral Blood Stem Cell Transplantation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16184583.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Zeglaoui I, Belcadhi M, Sriha B, Bouzouita K: Nasal NK/T-cell lymphoma in the paediatric population. Two case reports. B-ENT; 2009;5(2):119-23
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal NK/T-cell lymphoma in the paediatric population. Two case reports.
  • Nasal natural killer (NK)/T-cell lymphoma is an uncommon disease, and only a few paediatric cases are found in the literature.
  • We report 2 cases of NK/T-cell lymphoma occurring in children.
  • The primary site was the the nasal cavity in the first case (5-year-old girl) and the tonsil in the second case (4-year-old boy).
  • Both underwent an aggressive chemotherapy regimen.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670600.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


20. Pistevou-Gombaki K, Eleftheriadis N, Sofroniadis I, Makris P, Kouloulias V: Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate. J Exp Clin Cancer Res; 2002 Sep;21(3):429-32
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate.
  • We report a case of a 72-year-old male, with a known history of non-Hodgkin lymphoma of the left tonsil for two years, histologically proved and successfully treated by radical surgical excision in combination with external radiotherapy.
  • Despite the absence of related data in the current literature, we consider the use of high dose pamidronate intravenous therapy safe and an effective method of palliative management of painful osseous metastases from non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diphosphonates / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Pain / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Pain Measurement. Palliative Care / methods


21. Mele L, Pagano L, Equitani F, Chiusolo P, Rossi E, Zini G, Teofili L, Leone G: Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature. Haematologica; 2000 May;85(5):544-8
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature.
  • In this paper we describe a case of a 65-year old man with a lymphoid blastic crisis of a chronic granulocytic leukemia occurring seven years after a palatine tonsillar non-Hodgkin's lymphoma treated with chemotherapy and radiation therapy.
  • The patient died within a few months, unresponsive to any treatment.
  • [MeSH-minor] Aged. Bone Marrow Cells / pathology. Cytogenetics. Fatal Outcome. Fusion Proteins, bcr-abl / genetics. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Neoplasms, Second Primary. Palatine Tonsil / pathology. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800174.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] ITALY
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 40
  •  go-up   go-down


22. Dölken MT, Schüler F, Hirt C, Lorenz G, Hosten N, Dölken G: Multiple osteolytic lesions and testicular involvement at first relapse of follicular lymphoma grade 1 in transformation. Leuk Lymphoma; 2006 Feb;47(2):369-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple osteolytic lesions and testicular involvement at first relapse of follicular lymphoma grade 1 in transformation.
  • A 62-year-old man was initially diagnosed with stage IA follicular lymphoma grade 1 of the left tonsil.
  • Shortly after radiotherapy he rapidly developed multiple painful acroosteolytic lesions and testicular involvement.
  • The histological examination revealed a transformed lymphoma in the testis (DLCL) and follicular lymphoma in the acroosteolytic lesions.
  • The clonal identity of lymphoma cells within the primary biopsy as well as in the two sites at relapse was shown by PCR and nucleotide sequence analysis of the lymphoma clone specific B-cell receptor rearrangement.
  • Chemotherapy with six cycles of CHOP followed by high dose chemotherapy and autologous blood stem cell transplantation led to a complete clinical remission with disappearance of all osteolytic lesions.
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, Follicular / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Staging. Osteolysis / etiology. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction. Transplantation, Autologous. Treatment Outcome


23. Wang CP, Hsieh CY, Chang YL, Lou PJ, Yang TL, Ting LL, Ko JY: Postirradiated neuroendocrine carcinoma of the sinonasal tract. Laryngoscope; 2008 May;118(5):804-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this present study, we report our treatment experience with sinonasal NEC.
  • RESULTS: Ten tumors were primary NEC without previous radiation, and eight tumors were postirradiated NEC occurring within the radiation field for previous nasopharyngeal carcinoma in six patients and tonsillar lymphoma in one and neck metastasis of unknown primary origin in one, with an interval between previous radiotherapy and diagnosis of NEC from 82 to 385 months, with a mean of 197 months.
  • Three patients received induction chemotherapy or primary radiotherapy with further definitive treatment.
  • In comparing primary NEC with postirradiated NEC, they were similar in age, sex distribution, stage, pathology, and treatment, and the 5-year overall survival rates were 70% and 62.5%, respectively.
  • The prognoses of postirradiated NEC and primary NEC appear to be similar despite the relatively short follow-up period in the postirradiated NEC group.
  • [MeSH-minor] Adult. Aged. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Combined Modality Therapy. Female. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Humans. Lymphoma / pathology. Lymphoma / radiotherapy. Male. Maxillary Neoplasms / secondary. Maxillary Neoplasms / surgery. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Radiotherapy Dosage. Retrospective Studies. Tonsillar Neoplasms / pathology. Tonsillar Neoplasms / radiotherapy. Tonsillar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520182.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Singh SK, Gupta AK, Jha V, Kohli HS, Gupta KL, Minz M, Sakhuja V: Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy. Transplant Proc; 2006 Sep;38(7):2088-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy.
  • Reduction or cessation of immunosuppressive therapy has been advocated in these cases to prevent tumor progression and recurrence.
  • We evaluated the outcome of treatment of oropharyngeal cancer (OC) after renal transplantation without cessation of immunosuppressive therapy.
  • METHODS: The database of patients with OC after renal transplantation was analyzed with respect to age, sex, type of immunosuppression, interval between transplantation and diagnosis of cancer, as well as method of treatment and survival.
  • RESULTS: Thirty one (2.06%) renal transplant recipients developed malignancy including 6 (20%) with OC.
  • Lingual cancer was seen in three, and one each showed an isolated tonsillar lymphoma, a parotid carcinoma, or a carcinoma of the larynx with only the last having had two other malignancies in the past.
  • Average time from transplantation to diagnosis of OC was 106 months.
  • The interval was the shortest (2 years) for tonsillar lymphoma in an 18-year-old patient who received cyclosporine and showed features of left follicular tonsillitis.
  • The patient with advanced carcinoma of the larynx did not receive any treatment and succumbed within 3 months.
  • The dose of cyclosporine was reduced in the lymphoma case but immunosuppression was not altered in the other patients.
  • CONCLUSION: Comprehensive treatment of OC after renal transplantation without withdrawing the immunosuppression prolonged the life of these patients with functioning grafts.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Kidney Transplantation / immunology. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980008.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


25. Melegh Z, Sutak J, Whiteway A, Rooney N, Pawade J: Lymphomatoid granulomatosis of the uterine cervix. Pathol Res Pract; 2009;205(5):371-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The disease was preceded by an immunosuppressive condition, namely low-grade lymphoplasmacytic lymphoma treated with chemotherapy.
  • [MeSH-major] Immunocompromised Host. Lymphomatoid Granulomatosis / immunology. Neoplasms, Second Primary / immunology. Uterine Cervical Neoplasms / immunology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Epstein-Barr Virus Infections / complications. Female. Humans. Immunohistochemistry. In Situ Hybridization. Palatine Tonsil / metabolism. Palatine Tonsil / pathology. RNA, Viral / analysis. Waldenstrom Macroglobulinemia / drug therapy. Waldenstrom Macroglobulinemia / pathology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147299.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epstein-Barr virus encoded RNA 2; 0 / RNA, Viral
  •  go-up   go-down


26. Qi J, Fan X, Wang C, Ma J, Tang H: [Unilateral tonsillar enlargement and malignant tonsillar lymphoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Sep;16(9):469-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unilateral tonsillar enlargement and malignant tonsillar lymphoma].
  • OBJECTIVE: To study clinic characters of malignant lymphoma in patients with unilateral tonsillar enlargement for early discover and synthetic therapy clinic characters of malignant lymphoma patients with unilateral tonsillar enlargement for early discover and synthetic therapy.
  • METHOD: 10 cases of non-Hodgkin's lymphoma (NHL) out of 100 unilateral tonsillar enlargement patients given tonsillectomy were treated with combined chemotherapy.
  • CONCLUSION: Progressing unilateral swollen tonsil found in a short time with suspicious appearance should be given tonsillectomy for histopathology; upper airway and systematic symptoms such as fever and rigors, night sweats; lymphatic enlargement in cervical, axillary, inguinal region; hepatosplenomegaly should be thought of main traits of malignant lymphoma, and hyposensitivity to medicine should be taken malignant lymphoma into account.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Tonsillectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15515534.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Ishida Y, Asahi A, Wada T, Kanai N, Kobayashi Y, Moriai S, Kishibe K, Harabuchi Y: [Three cases of methotrexate-associated lymphoproliferative disorder (MTX-LPD)]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Aug;111(8):594-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reported three case of rheumatoid arthritis (RA) undergoing methotrexate (MTX) therapy who developed MTX-LPD.
  • A 72-year-old woman treated with MTX since December 1997 (total dose 3684 mg) presented with swelling of the right tonsil in October 2006, and diffuse large B-cell lymphoma was diagnosed by tonsil biopsy and positive EBER1.
  • When MTX therapy was interrupted, the tonsil was shrank and chemotherapy was not necessary.
  • [MeSH-minor] Aged. Arthritis, Rheumatoid / drug therapy. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788425.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


28. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three cases arose from the maxillary sinus, two from the ethmoid sinus, one from the parotid gland, one from the tonsil, and one from the larynx.
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


29. Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Rémy-Martin JP, Callanan M, Traverse-Glehen A, GrandClément C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C: Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood; 2010 Mar 25;115(12):2420-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We established here that this novel, alternatively spliced CD20 transcript is expressed and detectable at various levels in leukemic B cells, lymphoma B cells, in vivo tonsil- or in vitro CD40L-activated B cells, and Epstein-Barr virus (EBV)-transformed B cells, but not in resting CD19(+)- or CD20(+)-sorted B cells from peripheral blood or bone marrow of healthy donors.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / genetics. Drug Resistance, Neoplasm / genetics. Leukemia, B-Cell / drug therapy. Membrane Proteins / genetics
  • [MeSH-minor] Alternative Splicing / physiology. Antibodies, Monoclonal, Murine-Derived. B-Lymphocytes / cytology. B-Lymphocytes / physiology. Blotting, Western. Cell Compartmentation. Cell Line, Transformed. Cell Line, Tumor. Humans. Mutagenesis, Site-Directed. Neoplasm, Residual / genetics. Neoplasm, Residual / pathology. Palatine Tonsil / cytology. RNA, Messenger / genetics. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20089966.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / MS4A4A protein, human; 0 / Membrane Proteins; 0 / RNA, Messenger; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


30. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • Seven of the relapses were in the pelvis, one submandibularily, one in the tonsil, and one in the axilla.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


31. Pinho-Apezzato ML, Tannuri U, Tannuri AC, Mello ES, Lima F, Gibelli NE, Santos MM, Ayoub AA, Maksoud-Filho JG, Velhote MC, Silva MM, Andrade WC, Miyatani HT: Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. Transplant Proc; 2010 Jun;42(5):1763-8
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The age at diagnosis ranged from 12 to 258 months (median, 47), and the time from transplantation ranged from 1 to 84 months (median, 13).
  • The clinical signs at presentation were anemia (92.3%), diarrhea and vomiting (69.2%), recurrent upper airway infections (38.4%), Waldeyer ring lymphoid tissue hypertrophy (23.0%), abdominal mass lesions (30.7%), massive cervical and mediastinal adenopathy (15.3%), or gastrointestinal and respiratory symptoms (30.7%).
  • One child developed fulminant hepatic allograft failure secondary to graft involvement by PTLD.
  • Polymorphic PTLD was diagnosed in 6 patients; 7 had the diagnosis of lymphoma.
  • Treatment consisted of stopping immunosuppression as well as starting intravenous gancyclovir and anti-CD20 monoclonal antibody therapy.
  • The other symptoms that may be linked to the diagnosis of PTLD are pancytopenia, tonsil and adenoid hypertrophy, cervical or mediastinal lymph node enlargement, as well as abdominal masses.
  • Despite numerous advances, the optimal treatment approach for PTLD is not completely known and the mortality rate is still high.
  • [MeSH-minor] Biliary Atresia / surgery. Child. Child, Preschool. Colonic Neoplasms / pathology. Cyclosporine / therapeutic use. Drug Therapy, Combination. Epstein-Barr Virus Infections / epidemiology. Female. Herpesvirus 4, Human / isolation & purification. Humans. Immunosuppressive Agents / therapeutic use. Infant. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Male. Prednisone / therapeutic use. Retrospective Studies. Survivors. Tacrolimus / therapeutic use

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20620519.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; VB0R961HZT / Prednisone; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


32. Ijichi K, Hasegawa Y, Ogawa T, Terada A, Hyodo I, Yamada H, Murakami S: [Investigation for cervical lymph node metastasis in unknown primary sites]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Nov;108(11):1083-90
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation for cervical lymph node metastasis in unknown primary sites].
  • In patients with cervical adenopathy, especially, those of cervical lymph node metastasis with no detectable primary tumor, diagnosis and treatment planning can become confused.
  • Primary sites were detected in 20 before treatment.
  • The other 36 patients clearly had no primary lesions when treatment started.
  • Primary sites were 5 cases of oropharynx, 2 of the parotid gland, and 1 each of larynx, nasopharynx, hypopharynx, and malignant lymphoma detected in 11 after treatment for cervical lymph nodes.
  • No primary lesion was found in 28 patients.
  • To detect the primary site, we conducted "random" biopsy, panendoscopy, and radiographic evaluation including FDG-PET.
  • Biopsy sites were the nasopharynx, palatine and lingual tonsil, and piriform sinus.
  • Some 35 patients (59.3%) underwent random biopsy, and primary sites were found this way in 5 patients (14.3%).
  • The 36 who had no primary lesion were treated for cervical lymph nodes, of whom 24 underwent neck dissection.
  • Chemotherapy and radiotherapy were the treatment of choice in many cases.
  • Analysis suggested that primary sites should be studied by CT, MRI, FDG-PET, and panendoscopy, including random biopsy.
  • The primary site cannot be detected, treatment should initially involve cervical adenopathy with combined surgery, chemotherapy, and radiotherapy.
  • After treatment, the patient should be followed up carefully to find the primary lesion.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Lymph Nodes / pathology. Neck Dissection / mortality. Neoplasms, Unknown Primary / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359003.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement